Search

Your search keyword '"DiNatale, Renzo G."' showing total 200 results

Search Constraints

Start Over You searched for: Author "DiNatale, Renzo G." Remove constraint Author: "DiNatale, Renzo G."
200 results on '"DiNatale, Renzo G."'

Search Results

7. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

8. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape

9. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy

13. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy

18. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma

21. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis

22. Localized Non‐Metastatic Sarcomatoid Renal Cell Carcinoma: A 31 Year Externally Verified Study

23. Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers

24. Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort

25. Localised non‐metastatic sarcomatoid renal cell carcinoma: a 31‐year externally verified study.

26. Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

27. Supplementary Figure from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

28. Data from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

29. Supplementary Data 2 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

30. Supplementary Data 1 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

31. Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

32. Additional file 2 of Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape

35. Figure S2 from Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression

39. Urethral Melanoma – Clinical, Pathological and Molecular Characteristics

41. Spatiotemporal evolution of the ccRCC microenvironment links intra-tumoral heterogeneity to immune escape

42. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

44. PD16-07 NEUTROPHIL-TO-LYMPHOCYTE RATIO IN UNCLASSIFIED RENAL CELL CARCINOMA IS ASSOCIATED WITH OUTCOME AND DIFFERS BETWEEN MOLECULAR SUBGROUPS

45. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma

46. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

47. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

48. Resource-efficient pooled sequencing expands translational impact in solid tumors

49. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

50. Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course

Catalog

Books, media, physical & digital resources